Regarding the use of EGFR targeting agents in advanced pancreatic cancer, the tumor KRAS status may play a role as a prognostic or even predictive biomarker: based on previous translational results from AIO-PK0104, a large randomized phase III trial comparing a treatment sequence of gemcitabine + erlotinib followed by capecitabine vs capecitabine + erlotinib followed by gemcitabine in patients with advanced disease, patients with a KRAS wildtype may have a prolonged survival compared to patients with KRAS exon 2 mutations[7]. Here, KRAS is linked to pancreatic neoplasm.